心的外傷後ストレス障害(PTSD)治療薬の世界市場2020-2024

◆英語タイトル:Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024
◆商品コード:TNV20FB117
◆発行会社(リサーチ会社):Technavio
◆発行日:2020年1月31日
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

「心的外傷後ストレス障害(PTSD)治療薬の世界市場2020-2024」は、心的外傷後ストレス障害(PTSD)治療薬について市場概要、市場規模、製品別(抗うつ薬、抗不安薬、その他のPTSD治療薬)分析、顧客状況、地域状況、市場の要因・課題・トレンド、企業状況、企業分析などを総合的にまとめて調査・分析したものです。
・エグゼクティブサマリー
・市場概要
・市場規模
・ファイブフォース分析
・心的外傷後ストレス障害(PTSD)治療薬の世界市場:製品別(抗うつ薬、抗不安薬、その他のPTSD治療薬)
・顧客状況
・地域状況
・市場の要因・課題・トレンド
・企業状況
・企業分析
【レポートの概要】

Global Post-Traumatic Stress Disorder (PSTD) Therapeutics Market 2020-2024
Technavio has been monitoring the global post-traumatic stress disorder (PSTD) therapeutics market and it is poised to grow by USD 909.86 mn during 2020-2024, progressing at a CAGR of 9% during the forecast period. Our reports on post-traumatic stress disorder (PSTD) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of PSTD. In addition, increasing initiatives by public and private organizations is anticipated to boost the growth of the post-traumatic stress disorder (PSTD) therapeutics market as well.

Market Segmentation

Technavio’s global post-traumatic stress disorder (PSTD) therapeutics market is segmented as below:
Product
• Antidepressants
• Anxiolytics
• Other PSTD therapeutics

Geographic segmentation
• APAC
• Europe
• MEA
• North America
• South America

Key Trends for post-traumatic stress disorder (PSTD) therapeutics market growth
This study identifies increasing initiatives by public and private organizations as the prime reasons driving the post-traumatic stress disorder (PSTD) therapeutics market growth during the next few years.

Prominent vendors in post-traumatic stress disorder (PSTD) therapeutics market
We provide a detailed analysis of around 25 vendors operating in the post-traumatic stress disorder (PSTD) therapeutics market, including some of the vendors such as AstraZeneca Plc, Azevan Pharmaceuticals Inc., Bionomics Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Mylan NV, Neurocrine Biosciences Inc., Novartis International AG and Pfizer Inc. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/global-post-traumatic-stress-disorder-ptsd-therapeutics-market-industry-analysis

About Technavio
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【レポートの目次】

1. Executive Summary
1. Market Overview
1. Market Landscape
1. Market ecosystem
2. Value chain analysis
1. Market Sizing
1. Market definition
2. Market segment analysis
3. Market size 2019
4. Market outlook: Forecast for 2019 – 2024
1. Five Forces Analysis
1. Five Forces Summary
2. Bargaining power of buyers
3. Bargaining power of suppliers
4. Threat of new entrants
5. Threat of substitutes
6. Threat of rivalry
7. Market condition
1. Market Segmentation by Product
1. Market segments
2. Comparison by Product placement
3. Antidepressants – Market size and forecast 2019-2024
4. Anxiolytics – Market size and forecast 2019-2024
5. Other PTSD therapeutics – Market size and forecast 2019-2024
6. Market opportunity by Product
1. Customer landscape
1. Overview
1. Geographic Landscape
1. Geographic segmentation
2. Geographic comparison
3. North America – Market size and forecast 2019-2024
4. APAC – Market size and forecast 2019-2024
5. Europe – Market size and forecast 2019-2024
6. South America – Market size and forecast 2019-2024
7. MEA – Market size and forecast 2019-2024
8. Key leading countries
9. Market opportunity by geography
1. Drivers, Challenges, and Trends
1. Market drivers
2. Volume driver – Demand led growth
3. Volume driver – Supply led growth
4. Volume driver – External factors
5. Volume driver – Demand shift in adjacent markets
6. Price driver – Inflation
7. Price driver – Shift from lower to higher priced units
8. Market challenges
9. Market trends
1. Vendor Landscape
1. Overview
2. Vendor landscape
3. Landscape disruption
1. Vendor Analysis
1. Vendors covered
2. Market positioning of vendors
3. AstraZeneca Plc
4. Azevan Pharmaceuticals Inc.
5. Bionomics Ltd.
6. Eli Lilly and Co.
7. GlaxoSmithKline Plc
8. H. Lundbeck AS
9. Mylan NV
10. Neurocrine Biosciences Inc.
11. Novartis International AG
12. Pfizer Inc.
1. Appendix
1. Scope of the report
2. Currency conversion rates for US$
3. Research methodology
4. List of abbreviations
Exhibits
1.Key Finding 1
2.Key Finding 2
3.Key Finding 3
4.Key Finding 4
5.Key Finding 5
6.Key Finding 6
7.Key Finding 7
8.Market in focus
9.Parent market
10.Market characteristics
11.Product / Service portfolio of key vendors included in the market definition
12.Market segments
13.Global – Market size and forecast 2019 – 2024 ($ million)
14.Global market: Year-over-year growth 2019 – 2024 (%)
15.Five forces analysis 2019 & 2024
16.Bargaining power of buyers
17.Bargaining power of suppliers
18.Threat of new entrants
19.Threat of substitutes
20.Threat of rivalry
21.Market condition – Five forces 2019
22.Product placement – Market share 2019-2024 (%)
23.Comparison by Product placement
24.Antidepressants – Market size and forecast 2019-2024 ($ million)
25.Antidepressants – Year-over-year growth 2019-2024 (%)
26.Anxiolytics – Market size and forecast 2019-2024 ($ million)
27.Anxiolytics – Year-over-year growth 2019-2024 (%)
28.Other PTSD therapeutics – Market size and forecast 2019-2024 ($ million)
29.Other PTSD therapeutics – Year-over-year growth 2019-2024 (%)
30. Market opportunity by Product
31.Customer landscape
32.Market share by geography 2019-2024 (%)
33.Geographic comparison
34.North America – Market size and forecast 2019-2024 ($ million)
35.North America – Year-over-year growth 2019-2024 (%)
36.APAC – Market size and forecast 2019-2024 ($ million)
37.APAC – Year-over-year growth 2019-2024 (%)
38.Europe – Market size and forecast 2019-2024 ($ million)
39.Europe – Year-over-year growth 2019-2024 (%)
40.South America – Market size and forecast 2019-2024 ($ million)
41.South America – Year-over-year growth 2019-2024 (%)
42.MEA – Market size and forecast 2019-2024 ($ million)
43.MEA – Year-over-year growth 2019-2024 (%)
44.Key leading countries
45.Market opportunity by geography ($ million)
46.Impact of drivers
47.Impact of challenges
48.Landscape disruption
49.Industry risks
50.Vendors covered
51.Market positioning of vendors
52.AstraZeneca Plc – Overview (1/3)
53.AstraZeneca Plc – Overview (2/3)
54.AstraZeneca Plc – Overview (3/3)
55.AstraZeneca Plc – Product and service
56.AstraZeneca Plc – Key offerings
57.AstraZeneca Plc – Key customers
58.AstraZeneca Plc – Segment focus
59.Azevan Pharmaceuticals Inc. – Overview (1/3)
60.Azevan Pharmaceuticals Inc. – Overview (2/3)
61.Azevan Pharmaceuticals Inc. – Overview (3/3)
62.Azevan Pharmaceuticals Inc. – Product and service
63.Azevan Pharmaceuticals Inc. – Key offerings
64.Azevan Pharmaceuticals Inc. – Key customers
65.Azevan Pharmaceuticals Inc. – Segment focus
66.Bionomics Ltd. – Overview (1/3)
67.Bionomics Ltd. – Overview (2/3)
68.Bionomics Ltd. – Overview (3/3)
69.Bionomics Ltd. – Business segments
70.Bionomics Ltd. – Key offerings
71.Bionomics Ltd. – Key customers
72.Bionomics Ltd. – Segment focus
73.Eli Lilly and Co. – Overview (1/3)
74.Eli Lilly and Co. – Overview (2/3)
75.Eli Lilly and Co. – Overview (3/3)
76.Eli Lilly and Co. – Business segments
77.Eli Lilly and Co. – Key offerings
78.Eli Lilly and Co. – Key customers
79.Eli Lilly and Co. – Segment focus
80.GlaxoSmithKline Plc – Overview (1/3)
81.GlaxoSmithKline Plc – Overview (2/3)
82.GlaxoSmithKline Plc – Overview (3/3)
83.GlaxoSmithKline Plc – Business segments
84.GlaxoSmithKline Plc – Key offerings
85.GlaxoSmithKline Plc – Key customers
86.GlaxoSmithKline Plc – Segment focus
87.H. Lundbeck AS – Overview (1/3)
88.H. Lundbeck AS – Overview (2/3)
89.H. Lundbeck AS – Overview (3/3)
90.H. Lundbeck AS – Product and service
91.H. Lundbeck AS – Key offerings
92.H. Lundbeck AS – Key customers
93.H. Lundbeck AS – Segment focus
94.Mylan NV – Overview (1/3)
95.Mylan NV – Overview (2/3)
96.Mylan NV – Overview (3/3)
97.Mylan NV – Business segments
98.Mylan NV – Key offerings
99.Mylan NV – Key customers
100.Mylan NV – Segment focus
101.Neurocrine Biosciences Inc. – Overview (1/3)
102.Neurocrine Biosciences Inc. – Overview (2/3)
103.Neurocrine Biosciences Inc. – Overview (3/3)
104.Neurocrine Biosciences Inc. – Business segments
105.Neurocrine Biosciences Inc. – Key offerings
106.Neurocrine Biosciences Inc. – Key customers
107.Neurocrine Biosciences Inc. – Segment focus
108.Novartis International AG – Overview (1/3)
109.Novartis International AG – Overview (2/3)
110.Novartis International AG – Overview (3/3)
111.Novartis International AG – Business segments
112.Novartis International AG – Key offerings
113.Novartis International AG – Key customers
114.Novartis International AG – Segment focus
115.Pfizer Inc. – Overview (1/3)
116.Pfizer Inc. – Overview (2/3)
117.Pfizer Inc. – Overview (3/3)
118.Pfizer Inc. – Business segments
119.Pfizer Inc. – Key offerings
120.Pfizer Inc. – Key customers
121.Pfizer Inc. – Segment focus
122.Currency conversion rates for US$
123.Research Methodology
124.Validation techniques employed for market sizing
125.Information sources
126.List of abbreviations



【掲載企業】

AstraZeneca Plc
Azevan Pharmaceuticals Inc.
Bionomics Ltd.
Eli Lilly and Co.
GlaxoSmithKline Plc
H. Lundbeck AS
Mylan NV
Neurocrine Biosciences Inc.
Novartis International AG
Pfizer Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[心的外傷後ストレス障害(PTSD)治療薬の世界市場2020-2024]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆